干扰素α1b联合利巴韦林对慢性丙型肝炎患者甲状腺功能的影响
x

请在关注微信后,向客服人员索取文件

篇名: 干扰素α1b联合利巴韦林对慢性丙型肝炎患者甲状腺功能的影响
TITLE:
摘要: 目的:观察干扰素α1b对慢性丙型肝炎(CHC)患者甲状腺功能的影响。方法:回顾性收集CHC患者90例,按是否合并甲状腺疾病分为甲亢组、甲减组、CHC组,各30例。3组患者均使用重组人干扰素α1b 40 μg,qod,联合利巴韦林0.1 g,tid,进行抗病毒治疗。所有患者均给予常规保肝及稳定甲状腺功能治疗。治疗前后,观察3组患者快速病毒学应答(RVR)、早期病毒学应答(EVR)、治疗结束时病毒学应答(ETVR)、持续病毒学应答(SVR)效果及甲亢组、甲减组患者三碘甲状腺原氨酸(T3)、甲状腺素(T4)、游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)、促甲状腺激素(TSH)水平变化。结果:治疗后,3组患者RVR、EVR、ETVR、SVR率均显著升高,与治疗前比较,差异有统计学意义(P<0.05)。治疗后,3组患者RVR、EVR、ETVR、SVR组间比较,差异无统计学意义(P>0.05);治疗后甲亢组、甲减组患者T3、T4、FT3、FT4、TSH水平与治疗前比较,差异无统计学意义(P>0.05)。结论:干扰素α1b联合利巴韦林治疗CHC合并甲状腺疾病可以获得良好的抗病毒效果且不加重原有甲状腺疾病。
ABSTRACT: OBJECTIVE: To observe the effects of recombinant human interferon (IFN) α1b on thyroid function of patients with chronic hepatitis C (CHC). METHODS:Retrospective collection 90 CHC patients, according to whether to merge with hyperthyroidism into hypothyroidism group, hypothyroidism group and CHC group,30 cases in each group. 3 groups were given IFN-α1b 40 μg, qod, combined with ribavirin 0.1 g, tid, for antiviral therapy. Before and after therapy, RVR, EVR, ETVR and SVR were observed in 3 groups, and the levels of T3, T4, FT3, FT4 and TSH were observed in hypothyroidism group, hypothyroidism group before and after antiviral therapy. RESULTS: After treatment, RVR, EVR, ETVR and SVR levels of 3 groups increased significantly,with statistical significance,compared with before treatment(P<0.05).After treatment, there was no statistical significance in RVR, EVR, ETVR and SVR among 3 groups, there was no statistical significance (P>0.05); there was no statistical significance in the levels of T3, T4, FT3, FT4 and TSH before and after treatment (P>0.05). CONCLUSIONS: IFN-α1b combined with ribavirin can obtain good antiviral effect and not worsen existing thyroid disease in the treatment of CHC complicated with thyroid disease.
期刊: 2016年第27卷第5期
作者: 杨永生,黄桂芹
AUTHORS: YANG Yongsheng,HUANG Guiqin
关键字: 干扰素α1b;慢性丙型肝炎;甲状腺疾病
KEYWORDS: Recombinant human interferon α1b; Chronic hepatitis C; Thyroid disease
阅读数: 257 次
本月下载数: 2 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!